Výsledky vyhledávání - "Kevin P. Tordoff"

Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge

Autor: J.A. Hewitt, Gloria S. Sivko, Conrad P. Quinn, Jarad Schiffer, K.L. Taylor, Gregory V. Stark, M. VanRaden, Kevin P. Tordoff, E. Glaze, E.O. Nuzum

Publikováno v: Vaccine. 34:6518-6528

Anthrax Vaccine Adsorbed (AVA, BioThrax) is approved by the US Food and Drug Administration for post-exposure prophylaxis (PEP) of anthrax in adults. The PEP schedule is 3 subcutaneous (SC) doses (0, 14 and 28 days), in conjunction with a 60 day cour

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6edce1e6e9bf8e3e7ef001aa457cbf2a
https://doi.org/10.1016/j.vaccine.2016.04.048

Zobrazit plný text záznamu

Efficacy and Immunogenicity of Single-Dose AdVAV Intranasal Anthrax Vaccine Compared to Anthrax Vaccine Absorbed in an Aerosolized Spore Rabbit Challenge Model

Autor: M. Scot Roberts, Kevin P. Tordoff, Jianfeng Zhang, Bo H. Andersen, Matthew Duchars, Gloria S. Sivko, Christine Shoemaker, Vyjayanthi Krishnan, Tsungwei Feng, Gregory V. Stark

Publikováno v: Clinical and Vaccine Immunology. 22:430-439

AdVAV is a replication-deficient adenovirus type 5-vectored vaccine expressing the 83-kDa protective antigen (PA83) fromBacillus anthracisthat is being developed for the prevention of disease caused by inhalation of aerosolizedB. anthracisspores. A n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439699016c75e8e4dc436f2ef352629e
https://doi.org/10.1128/cvi.00690-14

Zobrazit plný text záznamu

Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: Immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy

Autor: Yoshihiro Kawaoka, Kevin B. Walsh, Gregory V. Stark, Hugh Rosen, Michael B. A. Oldstone, James P. Long, John R. Teijaro, Amie J. Eisfeld, Kevin P. Tordoff

Publikováno v: Virology

Influenza infection of humans remains an important public health problem. Vaccine strategies result in a significant but only partial control (65–85%) of infection. Thus, chemotherapeutic approaches are needed to provide a solution both for vaccine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04acc777ff609015de132ad71969a073
https://doi.org/10.1016/j.virol.2014.01.003

Zobrazit plný text záznamu

Pathology and Pathophysiology of Inhalational Anthrax in a Guinea Pig Model

Autor: Gregory V. Stark, Crystal M. Briscoe, Emily S Syar, Sukjoon Park, Kevin P. Tordoff, Roy E. Barnewall, Daniel C. Sanford, Laurence Lemiale-Biérinx, Jamie L. Austin, Mario H. Skiadopoulos, Boris Ionin, Michael S. Anderson, Vladimir Savransky

Publikováno v: Infection and Immunity. 81:1152-1163

Nonhuman primates (NHPs) and rabbits are the animal models most commonly used to evaluate the efficacy of medical countermeasures against anthrax in support of licensure under the FDA's “Animal Rule.” However, a need for an alternative animal mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23af769619a4e35a259c9674f369920
https://doi.org/10.1128/iai.01289-12

Zobrazit plný text záznamu

Development of an Inhalational Bacillus anthracis Exposure Therapeutic Model in Cynomolgus Macaques

Autor: Lisa N. Henning, Gabriel T. Meister, Bryan D. Ray, Kevin P. Tordoff, Gregory V. Stark, Jason E. Comer, Katherine A. B. Knostman

Publikováno v: Clinical and Vaccine Immunology. 19:1765-1775

Appropriate animal models are required to test medical countermeasures to bioterrorist threats. To that end, we characterized a nonhuman primate (NHP) inhalational anthrax therapeutic model for use in testing anthrax therapeutic medical countermeasur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e704c0b598cd9bfa96aa0d32361101d2
https://doi.org/10.1128/cvi.00288-12

Zobrazit plný text záznamu

Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1

Autor: John E. Bigger, Kevin P. Tordoff, Eric M. Vela, Mathew A. Buccellato, Greg Stark

Publikováno v: Influenza and Other Respiratory Viruses. 6:328-340

Please cite this paper as: Vela et al. (2012) Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1. Influenza and Other Respiratory Viruses 6(5), 328–340. Background In 1997, highly pathogenic avian influe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33f20e1626943b9a925844597df59f70
https://doi.org/10.1111/j.1750-2659.2011.00321.x

Zobrazit plný text záznamu

Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors

Autor: Weilian Yang, Melvin L. Moeschberger, Sureshbabu Narayanasamy, Gong Wu, Staffan Eriksson, Michele Swindall, Youngjoo Byun, Kent J. Riley, Kevin P. Tordoff, Werner Tjarks, Peter J. Binns, Rolf F. Barth

Publikováno v: Proceedings of the National Academy of Sciences. 105:17493-17497

The purpose of the present study was to evaluate the effectiveness of a 3-carboranyl thymidine analogue (3CTA), 3-[5-{2-(2,3-dihydroxyprop-1-yl)- o -carboran-1-yl}pentan-1-yl] thymidine, designated N5–2OH, for boron neutron capture therapy (BNCT) o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94d5f24b4412a097d1565f1564a2cbc0
https://doi.org/10.1073/pnas.0809569105

Zobrazit plný text záznamu

Porphyromonas gingivalis-host interactions in a Drosophila melanogaster model

Autor: Ann L. Griffen, Christina O. Igboin, Melvin L. Moeschberger, Eugene J. Leys, Kevin P. Tordoff

Publikováno v: Infection and immunity. 79(1)

Porphyromonas gingivalis is a Gram-negative obligate anaerobe that has been implicated in the etiology of adult periodontitis. We recently introduced a Drosophila melanogaster killing model for examination of P. gingivalis -host interactions. In the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89522762352ef3168039c1a51f4a4d10
https://pubmed.ncbi.nlm.nih.gov/21041486

Zobrazit plný text záznamu

Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies

Autor: Rolf F. Barth, Gong Wu, Melvin L. Moeschberger, Robert A. Fenstermaker, Werner Tjarks, Kevin P. Tordoff, Kent J. Riley, Achintya K. Bandyopadhyaya, Peter J. Binns, Michael J. Ciesielski, Weilian Yang, Michele Swindall, Carol J. Wikstrand, Thomas J. Sferra

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 14(3)

Purpose: The purpose of the present study was to evaluate the anti–epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), cetuximab, (IMC-C225) and the anti-EGFRvIII mAb, L8A4, used in combination as delivery agents for boron neutron ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca60038feb5ac81459bbbdf0171a65b
https://pubmed.ncbi.nlm.nih.gov/18245552

Zobrazit plný text záznamu

10 A Review of Statistical Analyses for Competing Risks

Autor: Melvin L. Moeschberger, Nidhi Kochar, Kevin P. Tordoff

This paper reviews the statistical analyses of competing risks data. There is an extensive history of this topic; however, the literature is often confusing partially because it evolved over time. The available data for competing risks is in the form

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a8d49ca347560d8cafd715c156f7122
https://doi.org/10.1016/s0169-7161(07)27010-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání